Equities researchers at J P Morgan Chase & Co started coverage on shares of Repligen (NASDAQ:RGEN) in a research note issued to investors on Tuesday, Marketbeat reports. The brokerage set an “overweight” rating and a $42.00 price target on the biotechnology company’s stock. J P Morgan Chase & Co’s target price indicates a potential upside of 22.31% from the company’s current price.

Other equities research analysts have also issued research reports about the stock. TheStreet raised shares of Repligen from a “c+” rating to a “b-” rating in a report on Friday, August 11th. BidaskClub raised shares of Repligen from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Zacks Investment Research raised shares of Repligen from a “hold” rating to a “buy” rating and set a $43.00 target price on the stock in a report on Thursday, October 5th. Jefferies Group reaffirmed a “hold” rating and issued a $40.00 target price on shares of Repligen in a report on Thursday, September 14th. Finally, First Analysis raised shares of Repligen from an “equal weight” rating to an “overweight” rating and set a $47.00 target price on the stock in a report on Monday, October 2nd. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $44.29.

Shares of Repligen (NASDAQ:RGEN) traded down $1.17 during trading on Tuesday, reaching $34.34. 412,500 shares of the company’s stock traded hands, compared to its average volume of 324,497. The company has a market cap of $1,547.00, a price-to-earnings ratio of 61.22, a PEG ratio of 2.31 and a beta of 1.04. Repligen has a 12-month low of $28.48 and a 12-month high of $46.81.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.04. The firm had revenue of $36.58 million for the quarter, compared to analyst estimates of $35.69 million. Repligen had a net margin of 16.93% and a return on equity of 7.57%. The business’s revenue for the quarter was up 48.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.08 EPS. analysts expect that Repligen will post 0.61 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Quantbot Technologies LP acquired a new position in Repligen during the 2nd quarter worth about $120,000. Oppenheimer Asset Management Inc. acquired a new position in Repligen during the 2nd quarter worth about $123,000. Victory Capital Management Inc. lifted its position in Repligen by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 4,001 shares of the biotechnology company’s stock worth $166,000 after buying an additional 601 shares in the last quarter. SG Americas Securities LLC acquired a new position in Repligen during the 3rd quarter worth about $180,000. Finally, Pinebridge Investments L.P. lifted its position in Repligen by 1.7% during the 2nd quarter. Pinebridge Investments L.P. now owns 4,491 shares of the biotechnology company’s stock worth $186,000 after buying an additional 76 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/12/05/repligen-rgen-earns-overweight-rating-from-analysts-at-j-p-morgan-chase-co.html.

About Repligen

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Co. and related companies with MarketBeat.com's FREE daily email newsletter.